Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation

被引：3
作者：
Wood, Brian R. [1 ]
Kassaye, Seble G. [2 ]
Gerstoft, Jan [3 ]
机构：
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA USA
[2] Georgetown Univ, Dept Med, Washington, DC USA
[3] Univ Copenhagen, Dept Infect Dis, Rigshosp, Copenhagen, Denmark
来源：
AIDS | 2023年 / 37卷 / 04期
关键词：
RILPIVIRINE; FAILURE;
D O I：
10.1097/QAD.0000000000003476
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：689 / 691
页数：3
相关论文
共 50 条
  • [31] Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort
    Cervo, Adriana
    Russo, Antonio
    Di Carlo, Domenico
    De Vito, Andrea
    Fabeni, Lavinia
    D'Anna, Stefano
    Duca, Leonardo
    Colpani, Agnese
    Fois, Marco
    Zauli, Beatrice
    Mancarella, Giulia
    Carraro, Anna
    Bezenchek, Antonia
    Cozzi-Lepri, Alessandro
    Santoro, Maria Mercedes
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 34 : 141 - 144
  • [32] Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection-A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance
    Gerstenberg, Jacob
    Klinker, Hartwig
    Baier, Michael
    von Braun, Amrei
    Seybold, Ulrich
    Helbig, Carlotta
    Daeumer, Martin
    Korn, Klaus
    Stephan, Christoph
    Schleenvoigt, Benjamin T.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [33] Learning From Full Characterization of HIV Proviruses in People Receiving Long-Acting Cabotegravir/Rilpivirine With a History of Replication on the Antiretroviral Classes
    Mchantaf, Gilbert
    Chaillon, Antoine
    Charre, Caroline
    Melard, Adeline
    Gardiennet, Elise
    Guinard, Jerome
    Prazuck, Thierry
    Guillaume, Clemence
    Mariaggi, Alice-Andree
    Bois, Julie
    Hocqueloux, Laurent
    Avettand-Fenoel, Veronique
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (01):
  • [34] Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir plus Rilpivirine Long-Acting Into European Clinical Settings
    Jonsson-Oldenbuettel, Celia
    Ghosn, Jade
    van der Valk, Marc
    Florence, Eric
    Vera, Francisco
    De Wit, Stephane
    Rami, Agathe
    Bonnet, Fabrice
    Hocqueloux, Laurent
    Hove, Kai
    Ait-Khaled, Mounir
    DeMoor, Rebecca
    Bontempo, Gilda
    Latham, Christine L.
    Gutner, Cassidy A.
    Iyer, Supriya
    Gill, Martin
    Czarnogorski, Maggie
    D'Amico, Ronald
    van Wyk, Jean
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (05) : 472 - 480
  • [35] Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment
    Baert, Lieven
    van 't Klooster, Gerben
    Dries, Willy
    Francois, Marc
    Wouters, Alfons
    Basstanie, Esther
    Iterbeke, Koen
    Stappers, Fred
    Stevens, Paul
    Schueller, Laurent
    Van Remoortere, Pieter
    Kraus, Guenter
    Wigerinck, Piet
    Rosier, Jan
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 72 (03) : 502 - 508
  • [36] Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy
    Moffatt, Kurtis
    Tekko, Ismaiel A.
    Vora, Lalitkumar
    Volpe-Zanutto, Fabiana
    Hutton, Aaron R. J.
    Mistilis, Jessica
    Jarrahian, Courtney
    Akhavein, Nima
    Weber, Andrew D.
    McCarthy, Helen O.
    Donnelly, Ryan F.
    PHARMACEUTICAL RESEARCH, 2023, 40 (07) : 1673 - 1696
  • [37] Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
    Thoueille, Paul
    Alves Saldanha, Susana
    Schaller, Fabian
    Munting, Aline
    Cavassini, Matthias
    Braun, Dominique
    Gunthard, Huldrych F.
    Kusejko, Katharina
    Surial, Bernard
    Furrer, Hansjakob
    Rauch, Andri
    Ustero, Pilar
    Calmy, Alexandra
    Stoeckle, Marcel
    Battegay, Manuel
    Marzolini, Catia
    Andre, Pascal
    Guidi, Monia
    Buclin, Thierry
    Decosterd, Laurent A.
    PHARMACEUTICS, 2022, 14 (08)
  • [38] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
    Rizzardini, Giuliano
    Overton, Edgar T.
    Orkin, Chloe
    Swindells, Susan
    Arasteh, Keikawus
    Gorgolas Hernandez-Mora, Miguel
    Pokrovsky, Vadim
    Girard, Pierre-Marie
    Oka, Shinichi
    Andrade-Villanueva, Jaime F.
    Richmond, Gary J.
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Griffith, Sandy
    Harrington, Conn M.
    Hudson, Krischan J.
    St Clair, Marty
    Talarico, Christine L.
    Patel, Parul
    Cutrell, Amy
    Van Eygen, Veerle
    D'Amico, Ronald
    Mrus, Joseph M.
    Wu, Sterling
    Ford, Susan L.
    Chow, Ken
    Roberts, Jeremy
    Wills, Angela
    Walters, Nicola
    Vanveggel, Simon
    Van Solingen-Ristea, Rodica
    Crauwels, Herta
    Smith, Kimberly Y.
    Spreen, William R.
    Margolis, David A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) : 498 - 506
  • [39] Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
    Patel, Parul
    Xue, Zhengyu
    King, Karen S.
    Parham, Laura
    Ford, Susan
    Lou, Yu
    Bakshi, Kalpana K.
    Sutton, Kenneth
    Margolis, David
    Hughes, Arlene R.
    Spreen, William R.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (08) : 2240 - 2248
  • [40] State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics
    Ravichandran, Shreya M.
    McFadden, William M.
    Snyder, Alexa A.
    Sarafianos, Stefan G.
    GLOBAL HEALTH & MEDICINE, 2024, 6 (05): : 285 - 294
12345